2-(1-oxo-5-(5-((5-oxo-2-thioxoimidazolidin-4-ylidene)-methyl)thiophen-2-yl)isoindolin-2-yl)ethyl acetate | 1313397-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(1-oxo-5-(5-((5-oxo-2-thioxoimidazolidin-4-ylidene)-methyl)thiophen-2-yl)isoindolin-2-yl)ethyl acetate
• 英文别名: (E,Z)-2-(1-oxo-5-(5-((5-oxo-2-thioxoimidazolidin-4-ylidene)methyl)thiophen-2-yl)isoindolin-2-yl)ethyl acetate；2-[3-oxo-6-[5-[(5-oxo-2-sulfanylideneimidazolidin-4-ylidene)methyl]thiophen-2-yl]-1H-isoindol-2-yl]ethyl acetate
• CAS: 1313397-73-7
• 化学式: C₂₀H₁₇N₃O₄S₂
• 分子量: 427.505
• InChiKey: HAVXAOUAJZQMMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  148
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(1-oxo-5-(5-((5-oxo-2-thioxoimidazolidin-4-ylidene)-methyl)thiophen-2-yl)isoindolin-2-yl)ethyl acetate 在 水 、 potassium carbonate 作用下， 以 甲醇 为溶剂， 以48%的产率得到2-(2-hydroxyethyl)-5-(5-((5-oxo-2-thioxoimidazolidin-4-ylidene)methyl)thiophen-2-yl)-isoindolin-1-one
  参考文献：
  名称：

  [EN] COMPOUNDS, PREPARATIONS AND USES THEREOF
  [FR] COMPOSÉS, LEURS PRÉPARATIONS ET LEURS UTILISATIONS

  摘要：

  本发明提供了式（I）的新化合物，包括这些化合物的药物组合物以及使用这些化合物作为抑制穿孔素活性的药剂或药物，用于治疗患有与不良穿孔素活性相关的疾病或紊乱、或处于患有风险或易感染某种疾病或紊乱的受试者的方法。

  公开号：

  WO2011075784A1
• 作为产物：
  描述：

  4-碘-2-甲基苯甲酸甲酯 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium fluoride 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 对甲苯磺酸 、 silver nitrate 、 溶剂黄146 、 β-丙氨酸 作用下， 以 四氢呋喃 、 水 、 二甲基亚砜 、 丙酮 、 苯 为溶剂， 反应 43.0h， 生成 2-(1-oxo-5-(5-((5-oxo-2-thioxoimidazolidin-4-ylidene)-methyl)thiophen-2-yl)isoindolin-2-yl)ethyl acetate
  参考文献：
  名称：

  Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein Perforin

  摘要：

  A series of novel 5-arylidene-2-thioxoimidazolidin-4-ones were investigated as inhibitors of the lymphocyte-expressed pore-forming protein perform. Structure activity relationships were explored through variation of an isoindolinone or 3,4-dihydroisoquinolinone subunit on a fixed 2-thioxoimidazolidin-4-one/thiophene core. The ability of the resulting compounds to inhibit the lytic activity of both isolated perform protein and perforin delivered in situ by natural killer cells was determined. A number of compounds showed excellent activity at concentrations that were nontoxic to the killer cells, and several were a significant improvement on previous classes of inhibitors, being substantially more potent and soluble. Representative examples showed rapid and reversible binding to immobilized mouse perforin at low concentrations (<= 2.5 mu M) by surface plasmon resonance and prevented formation of perforin pores in target cells despite effective target cell engagement, as determined by calcium influx studies. Mouse PK studies of two analogues showed T-1/2 values of 1.1-1.2 h (dose of 5 mg/kg iv) and MTDs of 60-80 mg/kg (ip).

  DOI：

  10.1021/jm401604x

文献信息

• COMPOUNDS, PREPARATION AND USES THEREOF
  申请人：Spicer Julie Ann

  公开号：US20130065897A1

  公开（公告）日：2013-03-14

  The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity.

  本发明提供了公式I的新化合物，包括这些化合物的制药组合物以及使用这些化合物作为抑制穿孔素活性的药剂或药物的方法，以及用于治疗处于风险或易感疾病或紊乱，或具有与不良穿孔素活性相关的疾病或紊乱的受试者。
• COMPOUNDS, PREPARATIONS AND USES THEREOF
  申请人：Peter MacCallum Cancer Institute

  公开号：EP2515903A1

  公开（公告）日：2012-10-31